GlassScriptPhysician profile
Casey Kay Clark
NPI 1710646542
$560.72
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.04 · 2022: $495.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $203.76 | 2022 | |
| Lilly USA, LLC | $90.71 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $89.60 | 2022 | |
| Novo Nordisk INC | $38.30 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.54 | 2022 | |
| Currax Pharmaceuticals LLC | $26.22 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.28 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.45 | 2021 | |
| Amgen INC. | $15.01 | 2022 | |
| Amarin Pharma, INC. | $12.85 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.